Prosecution Insights
Last updated: November 20, 2026
Application No. 18/723,454

ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Non-Final OA §112
Filed
Jun 23, 2024
Priority
Dec 23, 2021 — provisional 63/293,451 +1 more
Examiner
ALAM, DANYAL HASSAN
Art Unit
1672
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Novavax Inc.
OA Round
1 (Non-Final)
67%
Grant Probability
Favorable
1-2
OA Rounds
9m
Est. Remaining
67%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
6 granted / 9 resolved
+6.7% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
65 currently pending
Career history
65
Total Applications
across all art units

Statute-Specific Performance

§101
9.4%
-30.6% vs TC avg
§103
37.4%
-2.6% vs TC avg
§102
12.6%
-27.4% vs TC avg
§112
32.7%
-7.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 9 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This is a National Stage Entry under 35 U.S.C. 371 of International Patent Application No. PCT/US2022/082331, filed on December 23, 2022. This application also claims priority to US Provisional Application No. 63/293,451, filed on December 23, 2021. Election/Restrictions Applicant’s election with traverse of the following species: For VL CDR1 in claims 1, 4, and 5, SEQ ID NO: 11; For VL CDR2 in claims 1, 4, and 5, SEQ ID NO: 15; For VL CDR3 in claims 1, 4, and 5, SEQ ID NO: 19; For VH CDR1 in claims 1, 4, and 5, SEQ ID NO: 23; For VH CDR2 in claims 1, 4, and 5, SEQ ID NO: 27; For VH CDR3 in claims 1, 4, and 5, SEQ ID NO: 31; For the VH sequence in claims 2, 3, and 10, SEQ ID NO: 5 For the VL sequence in claims 2, 3, and 10, SEQ ID NO: 1; and For the CoV S polypeptide epitope in claims 19 and 22, SEQ ID NO: 10, reading on claims 1 – 5, 10, 15 – 19, 22, 24, 25, and 29 in the reply filed on 09/25/2026 is acknowledged. The traversal is on the ground(s) that the election does not address whether the claims, considered as a whole and interpreted in light of the description, are technically related through the same or corresponding special technical features. This is not found persuasive because as discussed previously, and discussed in detail below, the species do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to constitute independent and distinct inventions within the meaning of 35 U.S.C. § 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. § 121 and 37 CFR 1.141 et seq. (MPEP § 803.04). The requirement is still deemed proper and is therefore made FINAL. Claims 1 – 5, 10, 15 – 19, 22, 24, 25, and 29 are under examination. Claim Objections Applicant is advised that should claim 3 be found allowable, claim 4 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). Claim Rejections - 35 USC § 112 - Indefiniteness The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1 – 5, 10, 15 – 19, 22, 24, 25, and 29 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1 – 5, 10, 15 – 19, 22, 24, 25, and 29 are rejected on the judicially-created basis that they contain an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). The improper Markush grouping includes species of the claimed invention that do not share both a substantial structural feature and a common use that flows from the substantial structural feature. The members of the improper Markush grouping do not share a substantial structural feature and a common use that flows from the substantial structural feature for the following reasons: MPEP 803.02 provides guidance on the analysis of a proper Markush group. Members of a proper Markush group are disclosed in the specification to possess at least one property in common which is mainly responsible for their function in the claimed relationship, and it is clear from their very nature or from the prior art that all of them possess this property. The MPEP further provides that in the members of a proper Markush group there should be (1) a common utility, and (2) a substantial structural feature essential to that utility. In the instant case, SEQ ID NO: 11 – 31 and 76 – 81 are amino acid sequences related to different CDRs, SEQ ID NO: 1 – 8, 74, and 75 are amino acid sequences related to variable chains, SEQ ID NO: 9, 10, 35 – 43, 72, 73, 90 – 139, and 145 – 147 are amino acid sequences related to different antibodies. These are general groupings of CDRS, variable chains, and antibodies (in separate claims) and do not suggest that these groupings share structural similarities. Regarding claim 2, the antibodies are described solely in terms of the heavy and light chain and do not indicate the specific CDRs. Without defining the CDRs, the combination of possible CDRs is vast based on just the heavy and light chain and does not ascertain one of skill to reasonably conclude which CDRs are encompassed with the heavy and light. The metes and bounds of the CDRs are not defined, thus, the claim is indefinite. Furthermore, the group of antibodies of the claims contain species with different CDR sets, variable chain sets, or antibody sets. It is well established in the art that the formation of an intact antigen-binding site of antibodies generally requires at least one variable region, each of which consists of three CDRs or hypervariable regions, which provide the majority of the contact residues for the binding of the antibody to its target epitope (Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295, under the heading “Fv Structure and Diversity in Three Dimensions”). The amino acid sequences and conformations of each of the heavy and light chain CDRs are critical in maintaining the antigen binding specificity and affinity, which is characteristic of the immunoglobulin. CDRs of VH interact with each other and have sequence specific interactions that affect antigen binding. Vu et al. (Molecular Immunology, 1997, hereinafter, “Vu”) teaches disulfide bonds between CDR1 or CDR2 and CD3 stabilize the structure the of the antigen binding site (Section: Stabilisation of long CDR3 loop by inter-CDR disulfide bond, ¶1, ¶5). Therefore, it is expected that all of the CDRs in their proper order and in the context of framework sequences which maintain their required conformation, are required in order to produce a protein having antigen-binding function and that proper association of heavy variable regions is required in order to form functional antigen binding sites. CDRs also affect the activity of antigen binding by exerting secondary changes to H1, also known as the accessible loop (Section: Importance of H1 loop in the camelid VHH antigen binding, ¶1). CDR1 overlaps with H1 and directly affects both primary binding as well as secondary features such as the rotation of antigen binding via H1 (Section: Importance of H1 loop in the camelid VHH antigen binding, ¶1, Figure 5). The variability of CDR3 affects the H1 loop, where a higher CDR3 variability increases the variability of H1, causing the binding of the antigen to occur at different angles (Section: Importance of H1 loop in the camelid VHH antigen binding, ¶4). Even small rotational differences result in large changes in affinity (Section: Importance of H1 loop in the camelid VHH antigen binding, ¶4). Therefore, it is the full set of CDRs that determines antigen binding function and so it is this set of CDRs that must match among members of a proper antibody genus. Said another way, it is the CDR set as a whole that is the substantial structural feature essential to the utility (antigen binding) of antibodies. Since the instant claims contain Markush groups with members of antibodies with differing CDR sets, the claims contain an improper Markush group and are rejected here. The dependent claims do not add additional clarity and, therefore, are also indefinite. In response to this rejection, Applicant should either amend the claim(s) to recite only individual species or grouping of species that share a substantial structural feature as well as a common use that flows from the substantial structural feature, or present a sufficient showing that the species recited in the alternative of the claims(s) in fact share a substantial structural feature as well as a common use that flows from the substantial structural feature. This is a rejection on the merits and may be appealed to the Board of Patent Appeals and Interferences in accordance with 35 U.S.C. §134 and 37 CFR 41.31(a)(1). Claim Rejections - 35 USC § 112 – Written Description The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1 – 5, 10, 15 – 19, 22, 24, 25, and 29 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the inventor was in possession of the claimed genus. See, e.g., Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1340, 94 USPQ2d 1161, 1167 (Fed. Cir. 2010); University of California v. Eli Lilly & Co., 119 F.3d 1559, 43 USPQ2d 1398 (Fed. Cir. 1997) at 1406; Juno Therapeutics, Inc. v. Kite Pharma, Inc., 10 F.4th 1330, 1337, 2021 USPQ2d 893 (Fed. Cir. 2021) ("[T]he written description must lead a person of ordinary skill in the art to understand that the inventor possessed the entire scope of the claimed invention. Ariad, 598 F.3d at 1353–54 ('[T]he purpose of the written description requirement is to ensure that the scope of the right to exclude, as set forth in the claims, does not overreach the scope of the inventor's contribution to the field of art as described in the patent specification.' (internal quotation marks omitted)."). A “representative number of species” means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. See AbbVie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc., 759 F.3d 1285, 1300, 111 USPQ2d 1780, 1790 (Fed. Cir. 2014). The issue is whether the skilled artisan would understand inventor to have invented, and been in possession of, the invention as claimed. The Federal Circuit has clarified the application of the written description requirement to inventions in the field of biotechnology. See University of California v. Eli Lilly and Co., 119 F.3d 1559, 1568,43 USPQ2d l398, 1406 (Fed. Cir. 1997). The Court stated that a written description of an invention requires a precise definition, one that defines the structural features of the chemical genus that distinguishes it from other chemical structures. A definition by function does not suffice to define the genus because it is only an indication of what the genus does, rather than what it is. Further, the Court held that to adequately describe a claimed genus, an applicant must describe a representative number of species of the claimed genus, and that one of skill in the art should be able to “visualize or recognize the identity of the members of the genus.” Instant claims 1 – 5, 10, 15 – 19, 22, 24, 25, and 29 broadly encompass a SARS-CoV-2 antibody or fragment thereof. The Specification has failed to sufficiently describe the structural features that must be retained by members of the claimed genus to establish a structure-function relationship with respect to the ability of the antibody-binding protein to bind a SARS-CoV-2 antibody. The claims define the protein based on what it does—not what it is. Additionally, the Specification has failed to sufficiently describe the structural features that must be retained by members of the claimed genus to establish a structure-function relationship with respect to binding to a SARS-CoV-2 glycoprotein. Claim 1 recites an antibody or fragment thereof that binds specifically to a SARS-CoV-2 glycoprotein. Claim 1 further limits the antibody or fragment thereof to comprise one of many VL CDR 1, 2, and 3 and VH CDR 1, 2, 3. While the claim does give a vague limitation of the possible CDRs that may comprise the antibody, this limitation does not impart enough structure to establish a structure-function relationship because the innumerable combinations of CDRs encompassed by the instant claims do not clarify which structural limitations must exist for there to be binding of a SARS-COV-2 glycoprotein. As such, the claim describes a countless amount of antibodies and antigen-binding fragments, namely the claim recites an innumerable amount of CDR combinations. It is unclear which structural limitations must exist within the innumerable combinations of CDRs encompassed by the instant claims for there to be binding of a SARS-COV-2 glycoprotein and therefore, the claims and specification do not establish a structure-function relationship with the ability to bind to SARS-CoV-2 glycoprotein. Claims 1 and 4 recite the antibody or fragment there of that binds to a SARS-CoV-2 glycoprotein can be comprised of at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to a sequence selected from a group of CDRs. For example, claim 1 recites the VL CDR1 can be comprised of at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to SEQ ID NO: 11. SEQ ID NO: 11 is 10 amino acids in length. A variant sharing 80% identity to SEQ ID NO: 11 can have anywhere from 1 to 2 substitutions, deletions or additions in any combination along any length of the sequence. Thus, just for a full set of CDRs comprised of SEQ ID NOs: 11 (10aa), 15 (7aa), 19 (9aa), 23 (5aa), 27 (16aa), and 31 (9aa), the instant claims encompass an enormous genus (202 + 201 + 201 + 201 + 203 + 201 = 8.480) comprising thousands of sequences. Furthermore, claims 1, 4, and 5 recite the antibody or fragment there of that binds to a SARS-CoV-2 glycoprotein can be comprised of 4 different VL CDR1s, 4 different VL CDR2s, 4 different VL CDR2s, 4 different VH CDR1s, 4 different VH CDR2s, and 4 different VH CDR3s in any combination. Thus, just for combinations of, the instant claims encompass an enormous genus (56 = 15,625) comprising thousands of sequences. Together, with CDR variants sharing at least 80% similarity, the instant claims encompass an innumerable number of antibodies or fragments thereof. Claims 2 and 3 recite the antibody or fragment thereof that binds to a SARS-CoV-2 glycoprotein can be comprised of at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 %, or 100 % identity to a sequence selected from a group of VH and VL. For example, claim 2 further recites the VH can be comprised at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 %, or 100 % identity to SEQ ID NO: 5. SEQ ID NO: 5 is 116 amino acids in length. A variant sharing 80% identity to SEQ ID NO: 5 can have anywhere from 1 to 23 substitutions, deletions or additions in any combination along any length of the sequence. Thus, just for substitutions with canonical amino acids alone, the instant claims encompass an enormous genus (2023 = 8.38 x 1011) comprising trillions upon trillions of sequences. Furthermore, claims 2, 3, and 10 recite the antibody or fragment there of that binds to a SARS-CoV-2 glycoprotein can be comprised of 4 different VH and 4 different VL in any combination. Thus, just for combinations of variable chains, the instant claims encompass 25 different combinations. Together, with VH and VL variants sharing at least 80% similarity, the instant claims encompass an innumerable number of antibodies or fragments thereof. Claims 17 recites that the antibody or antigen-binding fragment binds to a SARS-COV-2 glycoprotein or variant thereof with a KD of 50 nM or less, 10 nM or less, 1 nM or less, 0.5 nM or less, 0.1 nM or less, 0.05 nM or less, 0.01 nM or less, or 0.001 nM or less, but does not define a lower limit. Therefore, even with six complete CDRs, there will always be an embodiment that is not possessed by Applicant. Furthermore, it is unclear which structural limitations must exist within the innumerable combinations of CDRs encompassed by the instant claims for there to be binding of a SARS-COV-2 glycoprotein at a specific KD. Claims 18 recites that the antibody or antigen-binding fragment binds to a SARS-COV-2 glycoprotein or variant thereof with a KD of less than 1.0 x 10-9 moles per liter (M), less than 1.0 x 10-10 M, less than 1.0 x 10-11 M, or less than 1.0 x 10-12 M, but does not define a lower limit. Therefore, even with six complete CDRs, there will always be an embodiment that is not possessed by Applicant. Furthermore, it is unclear which structural limitations must exist within the innumerable combinations of CDRs encompassed by the instant claims for there to be binding of a SARS-COV-2 glycoprotein at a specific KD. Claim 19 recites the antibody or fragment there of that binds to a SARS-CoV-2 glycoprotein can be comprised of at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 %, or 100 % identity to a sequence selected from SEQ ID NO: 9, 10, 35 – 43, 72, 73, 90 – 139, and 145 – 147. For example, claim 1 recites the VL CDR1 can be comprised of least 80 to SEQ ID NO: 9. SEQ ID NO: 9 is 1260 amino acids in length. A variant sharing 80% identity to SEQ ID NO: 9 can have anywhere from 1 to 252 substitutions, deletions or additions in any combination along any length of the sequence. Thus, just for substitutions with canonical amino acids alone, the instant claims encompass an enormous genus (20252 = 7.24 x 10327) comprising trillions upon trillions of sequences. Additionally, claims 22, 24, and 25 recite that the antibody or antigen-binding fragment binds to a SARS-COV-2 glycoprotein epitope. It is unclear which structural limitations must exist for there to be binding of a SARS-COV-2 glycoprotein epitope and therefore, the claim does not establish a structure-function relationship with the ability to bind to SARS-CoV-2 glycoprotein epitope let alone different epitopes. While the instant claims are drawn to a genus that comprises innumerable number of antibodies, the Specification has only adequately described and successfully reduced to practice 4 antibodies (Figures 1 – 6). However, this is not representative of the extremely large genus of antibodies claimed. The data generated for the select antibodies or antigen binding fragments described in the Specification and Drawings cannot reasonably be extrapolated and applied to support possession of the entire claimed genus of antibodies or antigen binding fragment because no structure-function relationship is established as to amino acid sequence and function amongst the claimed genus. As in Ariad, merely drawing a fence around the outer limits of a purported genus is not an adequate substitute for describing a variety of materials constituting the genus and showing that one has invented a genus and not just a species. “A patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion.” Brenner v. Manson, 383 U.S. 519, 536 (1966). Moreover, Rudikoff et al (PNAS, 1982, hereinafter, “Rudikoff”) teaches that highly similar antibody structures do not result in predictable function. Rudikoff teaches the CDR plays a key role in the target affinity of an antibody, showing that even a single amino acid alteration in the CDR can result in loss of antigen-binding function (Section: Implications for Generation of Diversity). Because the properties and function of an antibody are highly dependent upon the amino acid sequences and exact combination of CDRs, wherein, even one amino acid difference in a CDR region leads to different functional properties, different conformations of CDR sequences would result in antibodies or antigen-binding fragments having different properties. Furthermore, Einav et al (bioRxiv, 2020, hereinafter, “Einav”) teaches models of antibody mixtures through simulation. Einav teaches that even though models can be used to account for to help predict the activity of antibody mixtures, it can be “difficult to predict how antibodies will behave when mixed together, even after each has been independently characterized” (Abstract). Thus, when taken with the teachings of Rudikoff and Einav, one of skill in the art would readily appreciate that mere knowledge of structure alone cannot serve as the basis to describe members of the genus that have the recited function because a single antibody’s structure is unpredictable, let alone when combined with other antibodies of similar structure. In the absence of a representative number of examples, the Specification must at least describe the structural features that are required for the claimed function, in this case binding to a target protein. However, as discussed above, the Specification fails to describe any substantive structural limitations as to establish a structure-function relationship with respect to epitope binding activity. The Specification also fails to describe which regions, domains, etc. of the antibody sequences must be retained in order to bind to the target protein such as TNFalpha. Instead, Applicant merely offers a cursory statement that any antibody or antigen-binding polypeptide that binds to an epitope will work. Accordingly, the claims as currently written are not adequately described and one of skill in the art would readily appreciate that Applicant was not in possession of the claimed genus at the time of filing. Conclusion NO CLAIMS ARE ALLOWED Any inquiry concerning this communication or earlier communications from the examiner should be directed to Danyal H Alam whose telephone number is (571)272-1102. The examiner can normally be reached M - F 9am - 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas J. Visone can be reached at 571-270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DANYAL HASSAN ALAM/Examiner, Art Unit 1672 /THOMAS J. VISONE/Supervisory Patent Examiner, Art Unit 1672
Read full office action

Prosecution Timeline

Jun 23, 2024
Application Filed
Oct 30, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12625138
ANTIBODY FOR PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF
3y 1m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 1 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
67%
Grant Probability
67%
With Interview (+0.0%)
3y 2m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 9 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month